Literature DB >> 32378679

[Combinatorial Vancomycin and Piperacillin/Tazobactam Results in Elevated Vancomycin Trough Concentration and Acute Kidney Injury: A Case Report].

Yoshiro Sakai1,2, Ryoko Miwa1, Masahiro Mitsuoka3, Hiroshi Watanabe2.   

Abstract

In the hospital, antibiotics are widely used to treat infections. We report a case of acute kidney injury (AKI) caused by an antibiotic drug combination. A 30-year-old Japanese male presented with lung metastases, pneumothorax, empyema, and methicillin-resistant Staphylococcus aureus (MRSA) infection. The patient received a combination of vancomycin and piperacillin/tazobactam, which resulted in elevated vancomycin trough concentration and subsequently in AKI. Renal function was restored upon vancomycin and piperacillin/tazobactam cessation. Though this patient had AKI most likely due to the combined use of two agents as has been reported in many cases, vancomycin trough concentration showed an unexpected abnormal increase when halting vancomycin treatment. This is the first report indicating a drug-drug interaction between vancomycin and piperacillin/tazobactam with unexpected abnormal vancomycin trough concentration, leading to AKI, additionally we think that there was a situation that he stressed against the kidney by a history of medications caused renal dysfunction and co-administration. We suggest that when using vancomycin in combination with piperacillin/tazobactam, the trough concentration of vancomycin must be confirmed simultaneously with renal function and evaluation, and that the combination of these two drugs should be minimized.

Entities:  

Keywords:  acute kidney injury; piperacillin/tazobactam; vancomycin; vancomycin trough concentration

Year:  2020        PMID: 32378679     DOI: 10.1248/yakushi.19-00234

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  1 in total

1.  Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin.

Authors:  Kaori Nakatani; Kenji Momo; Takashi Mimura; Eri Yoshiizumi; Tadanori Sasaki
Journal:  Clin Case Rep       Date:  2022-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.